The DOI matches its Crossref record; 126 of the 126 references it cites were found in a registry or an index.
Review of precision cancer medicine: Evolution of the treatment paradigm
Open accessAbstract
In recent years, biotechnological breakthroughs have led to identification of complex and unique biologic features associated with carcinogenesis. Tumor and cell-free DNA profiling, immune markers, and proteomic and RNA analyses are used to identify these characteristics for optimization of anticancer therapy in individual patients. Consequently, clinical trials have evolved, shifting from tumor type-centered to gene-directed, histology-agnostic, with innovative adaptive design tailored to biomarker profiling with the goal to improve treatment outcomes. A plethora of precision medicine trials have been conducted. The majority of these trials demonstrated that matched therapy is associated with superior outcomes compared to non-matched therapy across tumor types and in specific cancers. To improve the implementation of precision medicine, this approach should be used early in the course of the disease, and patients should have complete tumor profiling and access to effective matched therapy. To overcome the complexity of tumor biology, clinical trials with combinations of gene-targeted therapy with immune-targeted approaches (e.g., checkpoint blockade, personalized vaccines and/or chimeric antigen receptor T-cells), hormonal therapy, chemotherapy and/or novel agents should be considered. These studies should target dynamic changes in tumor biologic abnormalities, eliminating minimal residual disease, and eradicating significant subclones that confer resistance to treatment. Mining and expansion of real-world data, facilitated by the use of advanced computer data processing capabilities, may contribute to validation of information to predict new applications for medicines. In this review, we summarize the clinical trials and discuss challenges and opportunities to accelerate the implementation of precision oncology.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
The sequence of the human genome
Venter, J. C., Adams, M. D., Myers, E. W., Li, P. W., Mural, R. J., Sutton, G. G., Smith, H. O., Yandell, M., Evans, C. A., Holt, R. A., et al. (2001) · Science · doi:10.1126/science.1058040 · Cited by 13,909
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing
Gerlinger, M., Rowan, A. J., Horswell, S., Larkin, J., Endesfelder, D., Gronroos, E., Martinez, P., Matthews, N., Stewart, A., Tarpey, P., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1113205 · Cited by 7,774
A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast Cancer
Paik, S., Shak, S., Tang, G., Kim, C., Baker, J., Cronin, M., Baehner, F. L., Walker, M. G., Watson, D., Park, T., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa041588 · Cited by 6,277
Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
Kantoff, P. W., Higano, C. S., Shore, N. D., Berger, E. R., Small, E. J., Penson, D. F., Redfern, C. H., Ferrari, A. C., Dreicer, R., Sims, R. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001294 · Cited by 5,572
Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
Maude, S. L., Frey, N., Shaw, P. A., Aplenc, R., Barrett, D. M., Bunin, N. J., Chew, A., Gonzalez, V. E., Zheng, Z., Lacey, S. F., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1407222 · Cited by 5,413
Circulating Tumor Cells, Disease Progression, and Survival in Metastatic Breast Cancer
Cristofanilli, M., Budd, G. T., Ellis, M. J., Stopeck, A., Matera, J., Miller, M. C., Reuben, J. M., Doyle, G. V., Allard, W. J., Terstappen, L. W. M. M., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040766 · Cited by 4,593
EGFR Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib
Kobayashi, S., Boggon, T. J., Dayaram, T., Jänne, P. A., Kocher, O., Meyerson, M., Johnson, B. E., Eck, M. J., Tenen, D. G., & Halmos, B. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa044238 · Cited by 3,964
Tumour heterogeneity and resistance to cancer therapies
Dagogo-Jack, I., & Shaw, A. T. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.166 · Cited by 3,846
Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma
Zaretsky, J. M., Garcia-Diaz, A., Shin, D. S., Escuin-Ordinas, H., Hugo, W., Hu-Lieskovan, S., Torrejon, D. Y., Abril-Rodriguez, G., Sandoval, S., Barthly, L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1604958 · Cited by 3,237
Greaves, M., & Maley, C. C. (2012) · Nature · doi:10.1038/nature10762 · Cited by 3,162
Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden
Hellmann, M. D., Ciuleanu, T.-E., Pluzanski, A., Lee, J. S., Otterson, G. A., Audigier-Valette, C., Minenza, E., Linardou, H., Burgers, S., Salman, P., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1801946 · Cited by 3,063
Marabelle, A., Le, D. T., Ascierto, P. A., Di Giacomo, A. M., De Jesus-Acosta, A., Delord, J.-P., Geva, R., Gottfried, M., Penel, N., Hansen, A. R., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.02105 · Cited by 3,048
An immunogenic personal neoantigen vaccine for patients with melanoma
Ott, P. A., Hu, Z., Keskin, D. B., Shukla, S. A., Sun, J., Bozym, D. J., Zhang, W., Luoma, A., Giobbie-Hurder, A., Peter, L., et al. (2017) · Nature · doi:10.1038/nature22991 · Cited by 2,936
Overman, M. J., McDermott, R., Leach, J. L., Lonardi, S., Lenz, H.-J., Morse, M. A., Desai, J., Hill, A., Axelson, M., Moss, R. A., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30422-9 · Cited by 2,836
Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity
Spranger, S., Bao, R., & Gajewski, T. F. (2015) · Nature · doi:10.1038/nature14404 · Cited by 2,830
Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children
Drilon, A., Laetsch, T. W., Kummar, S., DuBois, S. G., Lassen, U. N., Demetri, G. D., Nathenson, M., Doebele, R. C., Farago, A. F., Pappo, A. S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1714448 · Cited by 2,824
Cancer regression in patients after transfer of genetically engineered lymphocytes
Morgan, R. A., Dudley, M. E., Wunderlich, J. R., Hughes, M. S., Yang, J. C., Sherry, R. M., Royal, R. E., Topalian, S. L., Kammula, U. S., Restifo, N. P., et al. (2006) · Science · doi:10.1126/science.1129003 · Cited by 2,603
Adoptive cell transfer as personalized immunotherapy for human cancer
Rosenberg, S. A., & Restifo, N. P. (2015) · Science · doi:10.1126/science.aaa4967 · Cited by 2,506
Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer
Sahin, U., Derhovanessian, E., Miller, M., Kloke, B.-P., Simon, P., Löwer, M., Bukur, V., Tadmor, A. D., Luxemburger, U., Schrörs, B., et al. (2017) · Nature · doi:10.1038/nature23003 · Cited by 2,488
Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer
Sparano, J. A., Gray, R. J., Makower, D. F., Pritchard, K. I., Albain, K. S., Hayes, D. F., Geyer, C. E., Dees, E. C., Goetz, M. P., Olson, J. A., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1804710 · Cited by 2,397
PD-L1 expression as a predictive biomarker in cancer immunotherapy
Patel, S. P., & Kurzrock, R. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0983 · Cited by 2,291
Self-citationTumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers
Goodman, A. M., Kato, S., Bazhenova, L., Patel, S. P., Frampton, G. M., Miller, V., Stephens, P. J., Daniels, G. A., & Kurzrock, R. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0386 · Cited by 2,264
Self-citationRosenberg, S. A., Yang, J. C., Sherry, R. M., Kammula, U. S., Hughes, M. S., Phan, G. Q., Citrin, D. E., Restifo, N. P., Robbins, P. F., Wunderlich, J. R., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0116 · Cited by 2,140
Overman, M. J., Lonardi, S., Wong, K. Y. M., Lenz, H.-J., Gelsomino, F., Aglietta, M., Morse, M. A., Van Cutsem, E., McDermott, R., Hill, A., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.76.9901 · Cited by 2,079
Participation in Cancer Clinical Trials: Race-, Sex-, and Age-Based Disparities
Murthy, V. H., Krumholz, H. M., & Gross, C. P. (2004) · JAMA · doi:10.1001/jama.291.22.2720 · Cited by 2,078
Standards and Guidelines for the Interpretation and Reporting of Sequence Variants in Cancer
Li, M. M., Datto, M., Duncavage, E. J., Kulkarni, S., Lindeman, N. I., Roy, S., Tsimberidou, A. M., Vnencak-Jones, C. L., Wolff, D. J., Younes, A., et al. (2017) · The Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2016.10.002 · Cited by 2,030
Self-citationCombined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma
Long, G. V., Stroyakovskiy, D., Gogas, H., Levchenko, E., de Braud, F., Larkin, J., Garbe, C., Jouary, T., Hauschild, A., Grob, J. J., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1406037 · Cited by 1,899
Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy
Brown, C. E., Alizadeh, D., Starr, R., Weng, L., Wagner, J. R., Naranjo, A., Ostberg, J. R., Blanchard, M. S., Kilpatrick, J., Simpson, J., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1610497 · Cited by 1,836
Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations
Hyman, D. M., Puzanov, I., Subbiah, V., Faris, J. E., Chau, I., Blay, J.-Y., Wolf, J., Raje, N. S., Diamond, E. L., Hollebecque, A., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1502309 · Cited by 1,764
Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs
Kris, M. G., Johnson, B. E., Berry, L. D., Kwiatkowski, D. J., Iafrate, A. J., Wistuba, I. I., Varella-Garcia, M., Franklin, W. A., Aronson, S. L., Su, P.-F., et al. (2014) · JAMA · doi:10.1001/jama.2014.3741 · Cited by 1,724
Kim, S. T., Cristescu, R., Bass, A. J., Kim, K.-M., Odegaard, J. I., Kim, K., Liu, X. Q., Sher, X., Jung, H., Lee, M., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0101-z · Cited by 1,654
The Sequence of the Human Genome
Venter, J. C., Smith, H. O., & Adams, M. D. (2015) · Clinical Chemistry · doi:10.1373/clinchem.2014.237016 · Cited by 1,648
Loss of PTEN Promotes Resistance to T Cell–Mediated Immunotherapy
Peng, W., Chen, J. Q., Liu, C., Malu, S., Creasy, C., Tetzlaff, M. T., Xu, C., McKenzie, J. A., Zhang, C., Liang, X., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0283 · Cited by 1,539
Johnson, L. A., Morgan, R. A., Dudley, M. E., Cassard, L., Yang, J. C., Hughes, M. S., Kammula, U. S., Royal, R. E., Sherry, R. M., Wunderlich, J. R., et al. (2009) · Blood · doi:10.1182/blood-2009-03-211714 · Cited by 1,418
Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma
Miao, D., Margolis, C. A., Gao, W., Voss, M. H., Li, W., Martini, D. J., Norton, C., Bossé, D., Wankowicz, S. M., Cullen, D., et al. (2018) · Science · doi:10.1126/science.aan5951 · Cited by 1,249
Marcus, L., Lemery, S. J., Keegan, P., & Pazdur, R. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-4070 · Cited by 1,176
Personalized vaccines for cancer immunotherapy
Sahin, U., & Türeci, Ö. (2018) · Science · doi:10.1126/science.aar7112 · Cited by 1,147
Le Tourneau, C., Delord, J.-P., Gonçalves, A., Gavoille, C., Dubot, C., Isambert, N., Campone, M., Trédan, O., Massiani, M.-A., Mauborgne, C., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00188-6 · Cited by 1,137
Parkhurst, M. R., Yang, J. C., Langan, R. C., Dudley, M. E., Nathan, D.-A. N., Feldman, S. A., Davis, J. L., Morgan, R. A., Merino, M. J., Sherry, R. M., et al. (2011) · Molecular Therapy · doi:10.1038/mt.2010.272 · Cited by 1,020
Le, D. T., Kim, T. W., Van Cutsem, E., Geva, R., Jäger, D., Hara, H., Burge, M., O’Neil, B., Kavan, P., Yoshino, T., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.02107 · Cited by 1,005
Davis, A. A., & Patel, V. G. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0768-9 · Cited by 960
The BATTLE Trial: Personalizing Therapy for Lung Cancer
Kim, E. S., Herbst, R. S., Wistuba, I. I., Lee, J. J., Blumenschein, G. R., Tsao, A., Stewart, D. J., Hicks, M. E., Erasmus, J., Gupta, S., et al. (2011) · Cancer Discovery · doi:10.1158/2159-8274.cd-10-0010 · Cited by 889
The Molecular Genetics of Philadelphia Chromosome–Positive Leukemias
Epstein, F. H., Kurzrock, R., Gutterman, J. U., & Talpaz, M. (1988) · New England Journal of Medicine · doi:10.1056/nejm198810133191506 · Cited by 837
Self-citation(2017) · doi:10.1158/1078-0432.ccr-16-3133 · Cited by 831
van Rooij, N., van Buuren, M. M., Philips, D., Velds, A., Toebes, M., Heemskerk, B., van Dijk, L. J. A., Behjati, S., Hilkmann, H., el Atmioui, D., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.47.7521 · Cited by 798
Massard, C., Michiels, S., Ferté, C., Le Deley, M.-C., Lacroix, L., Hollebecque, A., Verlingue, L., Ileana, E., Rosellini, S., Ammari, S., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-1396 · Cited by 783
Guidelines for Validation of Next-Generation Sequencing–Based Oncology Panels
Jennings, L. J., Arcila, M. E., Corless, C., Kamel-Reid, S., Lubin, I. M., Pfeifer, J., Temple-Smolkin, R. L., Voelkerding, K. V., & Nikiforova, M. N. (2017) · The Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2017.01.011 · Cited by 743
Molecular profiling of cancer patients enables personalized combination therapy: the I-PREDICT study
Sicklick, J. K., Kato, S., Okamura, R., Schwaederle, M., Hahn, M. E., Williams, C. B., De, P., Krie, A., Piccioni, D. E., Miller, V. A., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0407-5 · Cited by 707
Self-citationStevanović, S., Draper, L. M., Langhan, M. M., Campbell, T. E., Kwong, M. L., Wunderlich, J. R., Dudley, M. E., Yang, J. C., Sherry, R. M., Kammula, U. S., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.58.9093 · Cited by 682
The Role of Clinical Trial Participation in Cancer Research: Barriers, Evidence, and Strategies
Unger, J. M., Cook, E., Tai, E., & Bleyer, A. (2016) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_156686 · Cited by 665
Chabon, J. J., Simmons, A. D., Lovejoy, A. F., Esfahani, M. S., Newman, A. M., Haringsma, H. J., Kurtz, D. M., Stehr, H., Scherer, F., Karlovich, C. A., et al. (2016) · Nature Communications · doi:10.1038/ncomms11815 · Cited by 648
Von Hoff, D. D., Stephenson, J. J., Rosen, P., Loesch, D. M., Borad, M. J., Anthony, S., Jameson, G., Brown, S., Cantafio, N., Richards, D. A., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.5983 · Cited by 647
Koyama, S., Akbay, E. A., Li, Y. Y., Aref, A. R., Skoulidis, F., Herter-Sprie, G. S., Buczkowski, K. A., Liu, Y., Awad, M. M., Denning, W. L., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-1439 · Cited by 640
Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial
Rodon, J., Soria, J.-C., Berger, R., Miller, W. H., Rubin, E., Kugel, A., Tsimberidou, A., Saintigny, P., Ackerstein, A., Braña, I., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0424-4 · Cited by 578
Self-citationKonstantinopoulos, P. A., Waggoner, S., Vidal, G. A., Mita, M., Moroney, J. W., Holloway, R., Van Le, L., Sachdev, J. C., Chapman-Davis, E., Colon-Otero, G., et al. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2019.1048 · Cited by 563
Adaptive Randomization of Veliparib–Carboplatin Treatment in Breast Cancer
Rugo, H. S., Olopade, O. I., DeMichele, A., Yau, C., van ’t Veer, L. J., Buxton, M. B., Hogarth, M., Hylton, N. M., Paoloni, M., Perlmutter, J., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1513749 · Cited by 554
Personalized Medicine in a Phase I Clinical Trials Program: The MD Anderson Cancer Center Initiative
Tsimberidou, A.-M., Iskander, N. G., Hong, D. S., Wheler, J. J., Falchook, G. S., Fu, S., Piha-Paul, S., Naing, A., Janku, F., Luthra, R., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-1627 · Cited by 539
Self-citationHainsworth, J. D., Meric-Bernstam, F., Swanton, C., Hurwitz, H., Spigel, D. R., Sweeney, C., Burris, H. A., Bose, R., Yoo, B., Stein, A., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.75.3780 · Cited by 506
Self-citationKim, E. S., Bruinooge, S. S., Roberts, S., Ison, G., Lin, N. U., Gore, L., Uldrick, T. S., Lichtman, S. M., Roach, N., Beaver, J. A., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.73.7916 · Cited by 485
Adaptive Randomization of Neratinib in Early Breast Cancer
Park, J. W., Liu, M. C., Yee, D., Yau, C., van ’t Veer, L. J., Symmans, W. F., Paoloni, M., Perlmutter, J., Hylton, N. M., Hogarth, M., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1513750 · Cited by 454
Esserman, L. J., Berry, D. A., DeMichele, A., Carey, L., Davis, S. E., Buxton, M., Hudis, C., Gray, J. W., Perou, C., Yau, C., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.39.2779 · Cited by 438
André, F., Bachelot, T., Commo, F., Campone, M., Arnedos, M., Dieras, V., Lacroix-Triki, M., Lacroix, L., Cohen, P., Gentien, D., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70611-9 · Cited by 404
Besser, M. J., Shapira-Frommer, R., Itzhaki, O., Treves, A. J., Zippel, D. B., Levy, D., Kubi, A., Shoshani, N., Zikich, D., Ohayon, Y., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0380 · Cited by 388
Schwaederle, M., Zhao, M., Lee, J. J., Lazar, V., Leyland-Jones, B., Schilsky, R. L., Mendelsohn, J., & Kurzrock, R. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2016.2129 · Cited by 348
Self-citationWorst, B. C., van Tilburg, C. M., Balasubramanian, G. P., Fiesel, P., Witt, R., Freitag, A., Boudalil, M., Previti, C., Wolf, S., Schmidt, S., et al. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2016.06.009 · Cited by 330
POLE Proofreading Mutations Elicit an Antitumor Immune Response in Endometrial Cancer
van Gool, I. C., Eggink, F. A., Freeman-Mills, L., Stelloo, E., Marchi, E., de Bruyn, M., Palles, C., Nout, R. A., de Kroon, C. D., Osse, E. M., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0057 · Cited by 320
Andersen, R., Donia, M., Ellebaek, E., Borch, T. H., Kongsted, P., Iversen, T. Z., Hölmich, L. R., Hendel, H. W., Met, Ö., Andersen, M. H., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1879 · Cited by 317
Buffa, F. M., Camps, C., Winchester, L., Snell, C. E., Gee, H. E., Sheldon, H., Taylor, M., Harris, A. L., & Ragoussis, J. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-0489 · Cited by 308
Hofman, V., Ilie, M. I., Long, E., Selva, E., Bonnetaud, C., Molina, T., Vénissac, N., Mouroux, J., Vielh, P., & Hofman, P. (2011) · International Journal of Cancer · doi:10.1002/ijc.25819 · Cited by 304
Abd Elmageed, Z. Y., Yang, Y., Thomas, R., Ranjan, M., Mondal, D., Moroz, K., Fang, Z., Rezk, B. M., Moparty, K., Sikka, S. C., et al. (2014) · Stem Cells · doi:10.1002/stem.1619 · Cited by 295
Huang, G. D., Bull, J., Johnston McKee, K., Mahon, E., Harper, B., & Roberts, J. N. (2018) · Contemporary Clinical Trials · doi:10.1016/j.cct.2018.01.003 · Cited by 294
Comoli, P., Pedrazzoli, P., Maccario, R., Basso, S., Carminati, O., Labirio, M., Schiavo, R., Secondino, S., Frasson, C., Perotti, C., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.6195 · Cited by 289
Stockley, T. L., Oza, A. M., Berman, H. K., Leighl, N. B., Knox, J. J., Shepherd, F. A., Chen, E. X., Krzyzanowska, M. K., Dhani, N., Joshua, A. M., et al. (2016) · Genome Medicine · doi:10.1186/s13073-016-0364-2 · Cited by 276
Schumacher, T. N. M. (2002) · Nature Reviews Immunology · doi:10.1038/nri841 · Cited by 274
A novel c-abl protein product in Philadelphia-positive acute lymphoblastic leukaemia
Kurzrock, R., Shtalrid, M., Romero, P., Kloetzer, W. S., Talpas, M., Trujillo, J. M., Blick, M., Beran, M., & Gutterman, J. U. (1987) · Nature · doi:10.1038/325631a0 · Cited by 270
Self-citationPan-cancer analysis of transcriptional metabolic dysregulation using The Cancer Genome Atlas
Rosario, S. R., Long, M. D., Affronti, H. C., Rowsam, A. M., Eng, K. H., & Smiraglia, D. J. (2018) · Nature Communications · doi:10.1038/s41467-018-07232-8 · Cited by 266
Chodon, T., Comin-Anduix, B., Chmielowski, B., Koya, R. C., Wu, Z., Auerbach, M., Ng, C., Avramis, E., Seja, E., Villanueva, A., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-3017 · Cited by 259
Goodman, A. M., Piccioni, D., Kato, S., Boichard, A., Wang, H.-Y., Frampton, G., Lippman, S. M., Connelly, C., Fabrizio, D., Miller, V., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2018.1701 · Cited by 247
Self-citationHerbst, R. S., Gandara, D. R., Hirsch, F. R., Redman, M. W., LeBlanc, M., Mack, P. C., Schwartz, L. H., Vokes, E., Ramalingam, S. S., Bradley, J. D., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-3473 · Cited by 244
Cancer Therapy Directed by Comprehensive Genomic Profiling: A Single Center Study
Wheler, J. J., Janku, F., Naing, A., Li, Y., Stephen, B., Zinner, R., Subbiah, V., Fu, S., Karp, D., Falchook, G. S., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-3043 · Cited by 238
Self-citationCooley, S., He, F., Bachanova, V., Vercellotti, G. M., DeFor, T. E., Curtsinger, J. M., Robertson, P., Grzywacz, B., Conlon, K. C., Waldmann, T. A., et al. (2019) · Blood Advances · doi:10.1182/bloodadvances.2018028332 · Cited by 236
Heller, G., McCormack, R., Kheoh, T., Molina, A., Smith, M. R., Dreicer, R., Saad, F., de Wit, R., Aftab, D. T., Hirmand, M., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.75.2998 · Cited by 228
Lee, J., Kim, S. T., Kim, K., Lee, H., Kozarewa, I., Mortimer, P. G. S., Odegaard, J. I., Harrington, E. A., Lee, J., Lee, T., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-0442 · Cited by 228
Circulating tumor cells in small-cell lung cancer: a predictive and prognostic factor
Hiltermann, T. J. N., Pore, M. M., van den Berg, A., Timens, W., Boezen, H. M., Liesker, J. J. W., Schouwink, J. H., Wijnands, W. J. A., Kerner, G. S. M. A., Kruyt, F. A. E., et al. (2012) · Annals of Oncology · doi:10.1093/annonc/mds138 · Cited by 224
Merker, J. D., Oxnard, G. R., Compton, C., Diehn, M., Hurley, P., Lazar, A. J., Lindeman, N., Lockwood, C. M., Rai, A. J., Schilsky, R. L., et al. (2018) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2018-0901-sa · Cited by 220
Self-citationTsimberidou, A.-M., Wen, S., Hong, D. S., Wheler, J. J., Falchook, G. S., Fu, S., Piha-Paul, S., Naing, A., Janku, F., Aldape, K., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0603 · Cited by 211
Self-citationGong, J., Wang, C., Lee, P. P., Chu, P., & Fakih, M. (2017) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2017.0016 · Cited by 207
Aisner, D. L., Sholl, L. M., Berry, L. D., Rossi, M. R., Chen, H., Fujimoto, J., Moreira, A. L., Ramalingam, S. S., Villaruz, L. C., Otterson, G. A., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-2289 · Cited by 206
Analysis of microRNA-target interactions across diverse cancer types
Jacobsen, A., Silber, J., Harinath, G., Huse, J. T., Schultz, N., & Sander, C. (2013) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.2678 · Cited by 196
Rationale and Design of the Targeted Agent and Profiling Utilization Registry Study
Mangat, P. K., Halabi, S., Bruinooge, S. S., Garrett-Mayer, E., Alva, A., Janeway, K. A., Stella, P. J., Voest, E., Yost, K. J., Perlmutter, J., et al. (2018) · JCO Precision Oncology · doi:10.1200/po.18.00122 · Cited by 189
Trédan, O., Wang, Q., Pissaloux, D., Cassier, P., de la Fouchardière, A., Fayette, J., Desseigne, F., Ray-Coquard, I., de la Fouchardière, C., Frappaz, D., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz080 · Cited by 189
Papadimitrakopoulou, V., Lee, J. J., Wistuba, I. I., Tsao, A. S., Fossella, F. V., Kalhor, N., Gupta, S., Byers, L. A., Izzo, J. G., Gettinger, S. N., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.66.0084 · Cited by 183
Precision Oncology: The UC San Diego Moores Cancer Center PREDICT Experience
Schwaederle, M., Parker, B. A., Schwab, R. B., Daniels, G. A., Piccioni, D. E., Kesari, S., Helsten, T. L., Bazhenova, L. A., Romero, J., Fanta, P. T., et al. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0795 · Cited by 182
Self-citationKageyama, S., Ikeda, H., Miyahara, Y., Imai, N., Ishihara, M., Saito, K., Sugino, S., Ueda, S., Ishikawa, T., Kokura, S., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1559 · Cited by 179
Azad, N. S., Gray, R. J., Overman, M. J., Schoenfeld, J. D., Mitchell, E. P., Zwiebel, J. A., Sharon, E., Streicher, H., Li, S., McShane, L. M., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.00818 · Cited by 169
Tsimberidou, A. M., Hong, D. S., Ye, Y., Cartwright, C., Wheler, J. J., Falchook, G. S., Naing, A., Fu, S., Piha-Paul, S. A., Jankú, F., et al. (2017) · JCO Precision Oncology · doi:10.1200/po.17.00002 · Cited by 167
Self-citationJhaveri, K. L., Wang, X. V., Makker, V., Luoh, S.-W., Mitchell, E. P., Zwiebel, J. A., Sharon, E., Gray, R. J., Li, S., McShane, L. M., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz291 · Cited by 151
Forget, M., Haymaker, C., Hess, K. R., Meng, Y. J., Creasy, C. A., Karpinets, T. V., Fulbright, O. J., Roszik, J., Woodman, S. E., Kim, Y. U., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-3649 · Cited by 143
ALKFusions in a Wide Variety of Tumor Types Respond to Anti-ALK Targeted Therapy
Ross, J. S., Ali, S. M., Fasan, O. O., Block, J. G., Pal, S. K., Elvin, J. A., Schrock, A. B., Suh, J. H., Nozad, S., Kim, S., et al. (2017) · The Oncologist · doi:10.1634/theoncologist.2016-0488 · Cited by 136
Tamminga, M., de Wit, S., Hiltermann, T. J. N., Timens, W., Schuuring, E. M. D., Terstappen, L. W. M. M., & Groen, H. J. M. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0649-2 · Cited by 120
T cell receptor gene therapy: strategies for optimizing transgenic TCR pairing
Govers, C., Sebestyén, Z., Coccoris, M., Willemsen, R. A., & Debets, R. (2010) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2009.12.004 · Cited by 104
Gene expression profiling may improve diagnosis in patients with carcinoma of unknown primary
Bridgewater, J. A., van Laar, R. K., Floore, A. N., & Veer, L. V. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604315 · Cited by 100
Proliferative potential and resistance to immune checkpoint blockade in lung cancer patients
Pabla, S., Conroy, J. M., Nesline, M., Glenn, S. T., Papanicolau‐Sengos, A., Burgher, B., Hagen, J., Giamo, V., Andreas, J., Lenzo, F. L., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0506-3 · Cited by 95
Self-citationGarassino, M. C., Rodríguez‐Abreu, D., Gadgeel, S. M., Esteban, E., Felip, E., Speranza, G., Reck, M., Hui, R., Boyer, M. J., Cristescu, R., et al. (2019) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2019.08.427 · Cited by 94
Tumor Heterogeneity and Therapeutic Resistance
Lovly, C. M., Salama, A. K. S., & Salgia, R. (2016) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_158808 · Cited by 77
Precision oncology for patients with advanced cancer: the challenges of malignant snowflakes
Kurzrock, R., & Giles, F. J. (2015) · Cell Cycle · doi:10.1080/15384101.2015.1041695 · Cited by 74
Self-citationLanger, C. J., Gadgeel, S. M., Borghaei, H., Patnaik, A., Powell, S. F., Gentzler, R. D., Yang, J. C., Gubens, M. A., Sequist, L. V. D., Awad, M. M., et al. (2019) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2019.08.426 · Cited by 66
Unique Molecular Landscapes in Cancer: Implications for Individualized, Curated Drug Combinations
Wheler, J. J., Lee, J. J., & Kurzrock, R. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-2329 · Cited by 64
Self-citationSecondary KIT mutations: the GIST of drug resistance and sensitivity
Napolitano, A., & Vincenzi, B. (2019) · British Journal of Cancer · doi:10.1038/s41416-019-0388-7 · Cited by 61
Improving Cancer Outcomes Through International Collaboration in Academic Cancer Treatment Trials
Trimble, E. L., Abrams, J. S., Meyer, R. M., Calvo, F. M., Cazap, E. L., Deye, J. A., Eisenhauer, E. A., FitzGerald, T. J., Lacombe, D. A., Parmar, M., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.5771 · Cited by 59
Circulating tumor DNA analysis in the era of precision oncology
Said, R., Guibert, N. M., Oxnard, G. R., & Tsimberidou, A. M. (2020) · Oncotarget · doi:10.18632/oncotarget.27418 · Cited by 53
Self-citationALCHEMIST: Bringing genomic discovery and targeted therapies to early‐stage lung cancer
Gerber, D. E., Oxnard, G., & Govindan, R. (2015) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.91 · Cited by 51
Development and validation of a gene expression tumour classifier for cancer of unknown primary
Tothill, R. W., Shi, F., Paiman, L., Bedő, J., Kowalczyk, A., Mileshkin, L., Buela, E., Klupacs, R., Bowtell, D. D. L., & Byron, K. A. (2014) · Pathology · doi:10.1097/pat.0000000000000194 · Cited by 48
Chae, Y. K., Vaklavas, C., Cheng, H. H., Hong, F., Harris, L. N., Mitchell, E. P., Zwiebel, J. A., McShane, L. M., Gray, R. J., Li, S., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.36.15_suppl.2503 · Cited by 45
CTCs 2020: Great Expectations or Unreasonable Dreams
Rossi, E. M. C., & Fabbri, F. (2019) · Cells · doi:10.3390/cells8090989 · Cited by 44
Signature program: a platform of basket trials
Slosberg, E. D., Kang, B. P. S., Peguero, J. A., Taylor, M. H., Bauer, T. M., Berry, D. A., Braiteh, F., Spira, A. I., Meric‐Bernstam, F., Stein, S., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.25109 · Cited by 41
Krop, I. E., Jegede, O. A., Grilley‐Olson, J. E., Lauring, J. D., Hamilton, S. R., Zwiebel, J. A., Li, S., Rubinstein, L., Doyle, A., Patton, D. R., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.36.15_suppl.101 · Cited by 41
The Marriage Between Genomics and Immunotherapy: Mismatch Meets Its Match
Subbiah, V., & Kurzrock, R. (2018) · The Oncologist · doi:10.1634/theoncologist.2017-0519 · Cited by 40
Self-citationCirculating Tumor Cells as a Predictor of Treatment Response in Clinically Localized Prostate Cancer
Salami, S. S., Singhal, U., Spratt, D. E., Palapattu, G. S., Hollenbeck, B. K., Schonhoft, J. D., Graf, R. P., Louw, J. E., Jendrisak, A., Dugan, L., et al. (2019) · JCO Precision Oncology · doi:10.1200/po.18.00352 · Cited by 32
Weidenbusch, B., Richter, G. H. S., Kesper, M. S., Guggemoos, M., Gall, K., Prexler, C., Kazantsev, I. V., Sipol, A. A., Lindner, L. H., Nathrath, M., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.25087 · Cited by 15
PBRM1 loss promotes tumour response to immunotherapy
Otto, G. P. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2018.12 · Cited by 6
PBRM1 loss promotes tumour response to immunotherapy
Otto, G. P. (2018) · Nature Reviews Nephrology · doi:10.1038/nrneph.2018.7 · Cited by 5
Transcriptome-based cancer type prediction for tumors of unknown origin.
Michuda, J., Igartua, C., Taxter, T., Bell, J. S. K., Pelossof, R. A., & White, K. P. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.2019.37.15_suppl.3081 · Cited by 4
Cited by
Yang, Y., Li, S., Wang, Y., Zhao, Y., & Li, Q. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01168-8 · Cited by 294
Kornauth, C., Pemovska, T., Vladimer, G. I., Bayer, G., Bergmann, M., Eder, S., Eichner, R., Erl, M., Esterbauer, H., Exner, R., et al. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-0538 · Cited by 206
“In contrast, a major 315 setback uniformly described in other personalized medicine trials is patient deterioration or 316 death during time of analysis (4,33).”
BackgroundPersonalizing neoadjuvant immune-checkpoint inhibition in patients with melanoma
Lucas, M. W., Versluis, J. M., Rozeman, E. A., & Blank, C. U. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00760-3 · Cited by 50
Ye, L., Zhao, G., Ma, J., Gan, Q., Luo, N., Pan, D., Chen, C., Chen, X., & Ning, S. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-026-02769-3 · Cited by 10
Learning chemical sensitivity reveals mechanisms of cellular response
Connell, W., Garcia, K., Goodarzi, H., & Keiser, M. J. (2024) · Communications Biology · doi:10.1038/s42003-024-06865-4 · Cited by 4
Metadata
- Authors
- Tsimberidou, A. M., Fountzilas, E., Nikanjam, M., & Kurzrock, R.
- Venue
- Cancer Treatment Reviews
- Publisher
- Elsevier BV
- Published
- 2020-06
- Volume
- 86
- Pages
- 102019
- ISSN
- 0305-7372 (ISSN-L)
- OpenAlex
- W3014115276
- Cited by
- 756
- References
- 126
- FWCI
- 23.59
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.